You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The Anti-allergic Cromones: Past, Present, and Future
|
|---|---|
| Published in |
Frontiers in Pharmacology, November 2017
|
| DOI | 10.3389/fphar.2017.00827 |
| Pubmed ID | |
| Authors |
Ajantha Sinniah, Samia Yazid, Roderick J. Flower |
| Abstract |
The anti-allergic cromones were originally synthesized in the 1960s by Fisons Plc, and the first drug to emerge from this program, disodium cromoglycate was subsequently marketed for the treatment of asthma and other allergic conditions. Whilst early studies demonstrated that the ability of the cromones to prevent allergic reactions was due to their 'mast cell stabilizing' properties, the exact pharmacological mechanism by which this occurred, remained a mystery. Here, we briefly review the history of these drugs, recount some aspects of their pharmacology, and discuss two new explanations for their unique actions. We further suggest how these findings could be used to predict further uses for the cromones. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 2 | 40% |
| United States | 1 | 20% |
| Switzerland | 1 | 20% |
| Unknown | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 60% |
| Practitioners (doctors, other healthcare professionals) | 2 | 40% |
Mendeley readers
The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 45 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 8 | 18% |
| Researcher | 6 | 13% |
| Student > Master | 6 | 13% |
| Student > Bachelor | 4 | 9% |
| Other | 3 | 7% |
| Other | 4 | 9% |
| Unknown | 14 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 13% |
| Medicine and Dentistry | 6 | 13% |
| Chemistry | 5 | 11% |
| Biochemistry, Genetics and Molecular Biology | 4 | 9% |
| Agricultural and Biological Sciences | 3 | 7% |
| Other | 7 | 16% |
| Unknown | 14 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 January 2018.
All research outputs
#13,058,343
of 23,007,887 outputs
Outputs from Frontiers in Pharmacology
#3,657
of 16,313 outputs
Outputs of similar age
#153,576
of 325,276 outputs
Outputs of similar age from Frontiers in Pharmacology
#59
of 261 outputs
Altmetric has tracked 23,007,887 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,313 research outputs from this source. They receive a mean Attention Score of 5.0. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 325,276 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 261 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.